Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 24, 2004 Brian Gorman	Abbott Labs Stirs Up Criticism With politicians and the public riled up about Medicare, Abbott hiked the cost of an HIV drug. Smart move?
The Motley Fool March 1, 2011 David Williamson	Glaxo Gets Its Day in Court GlaxoSmithKline and Rite-Aid are taking Abbott's HIV drug pricing to the courts.
The Motley Fool March 20, 2007 Brian Lawler	Smart Move by Abbott? Abbott takes a drastic measure to make a point about its patents. Thailand's actions offer a good warning of what can happen when governments try to intervene too much in existing markets.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool June 23, 2010 Kris Eddy	Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool April 1, 2011 Brian Orelli	Abbott: Battle Lost, War Won A jury ordered Abbott to pay GlaxoSmithKline $3.5 million. It could have been a lot worse.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
The Motley Fool July 30, 2010 Anand Chokkavelu	5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.
The Motley Fool September 24, 2010 Brian Orelli	Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front.
The Motley Fool April 4, 2011 Selena Maranjian	This Expense Could Wipe You Out You probably already realize that a significant amount of your spending in retirement will go toward health care. But you may still be surprised when you see the actual average price tag.
The Motley Fool September 15, 2010 Brian Orelli	Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer.
CFO Kris Frieswick	Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist...
BusinessWeek September 22, 2003	This Baby May Outdo Its Parent Some orphans are better off without their parents -- corporately speaking, that is. My hunch is this may apply to shares due to spring forth next year from health-care giant Abbott Laboratories.
The Motley Fool February 8, 2011 Brian Orelli	A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.
The Motley Fool December 1, 2009 Brian Orelli	Abbott Makes All the Right Moves Hot off its cholesterol win over Merck, Abbott Labs is playing it safe with another cholesterol drug, TriCor.
The Motley Fool January 7, 2005 Brian Gorman	Canadian Drug Sales Might End Drug makers may not have to worry about cheap pills flooding into the U.S. from across the border, at least for now, offering a small consolation to investors.
The Motley Fool March 18, 2004 Brian Gorman	The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool May 21, 2010 Brian Orelli	Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
The Motley Fool June 18, 2010 Denise Gellene	San Diego's Neurocrine Biosciences Scores Second Big Deal in Two Days The San Diego biotech agreed to grant German drug maker Boehringer Ingelheim and signed a pact with Abbott Labs.
The Motley Fool March 15, 2004 W.D. Crotty	60 Minutes on Drugs Will the weekly news magazine's prime-time slam rattle the drug stocks?
The Motley Fool January 30, 2007 Brian Lawler	Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap.
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool July 23, 2010 Bryan White	3 Buys Suffering From the Health-Care Hangover Three ideas in value territory for a much-needed sector.
The Motley Fool January 27, 2011 Rich Smith	What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool January 14, 2010 Jim Mueller	Roundtable: Which Health-Care Stocks to Buy Now Three Fool analysts give you their best ideas on where to put your money after the health-care reform bill makes it out of Congress.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
The Motley Fool July 19, 2004 Brian Gorman	Medicare Revises Stance on Obesity Medicare has added its two cents to the national conversation on the U.S.'s obesity problem, and its new policy has potentially important implications for many pharmaceutical companies.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool January 19, 2011 Brian Orelli	A Painfully Protracted Partner Depomed is in a bind.
The Motley Fool April 22, 2009 Selena Maranjian	Will Health-Care Reform Hurt Investors? The bad news here is that there's quite a bit of uncertainty around this issue, and that some health-care-focused companies may end up suffering. Read on to see who.
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
The Motley Fool January 31, 2007 Brian Lawler	You're Only Hurting Yourself, Thailand Thailand's decision to allow generics could do more harm than good. Investors, take note.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool December 30, 2010 Brian Orelli	This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly.
The Motley Fool September 16, 2010 Brian Orelli	Abbott's Product Line May Get Thinner Not that it needs the obesity drug.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.